Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Dingemans AC, de Langen AJ, van den Boogaart V, Marcus JT, Backes WH, Scholtens HTGM, van Tinteren H, Hoekstra OS, Pruim J, Brans B, Thunnissen FB, Smit EF, Groen HJM. Dingemans AC, et al. Among authors: de langen aj. Ann Oncol. 2011 Mar;22(3):559-566. doi: 10.1093/annonc/mdq391. Epub 2010 Aug 11. Ann Oncol. 2011. PMID: 20702788 Free article. Clinical Trial.
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Rosenberg EH, Heideman DAM, Radonic T, Smit EF. van Veggel B, et al. Among authors: de langen aj. Lung Cancer. 2018 Oct;124:130-134. doi: 10.1016/j.lungcan.2018.07.030. Epub 2018 Jul 30. Lung Cancer. 2018. PMID: 30268451 Free article.
Pembrolizumab for all PD-L1-positive NSCLC.
Smit EF, de Langen AJ. Smit EF, et al. Among authors: de langen aj. Lancet. 2019 May 4;393(10183):1776-1778. doi: 10.1016/S0140-6736(18)32559-5. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955976 No abstract available.
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
de Haan R, van den Heuvel MM, van Diessen J, Peulen HMU, van Werkhoven E, de Langen AJ, Lalezari F, Pluim D, Verwijs-Janssen M, Vens C, Schellens JHM, Steeghs N, Verheij M, van Triest B. de Haan R, et al. Among authors: de langen aj. Clin Cancer Res. 2021 Mar 1;27(5):1256-1266. doi: 10.1158/1078-0432.CCR-20-2551. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262140 Clinical Trial.
95 results